Bartlett & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Bartlett & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$82K	Hold	200	–	–	﹤0.01%	606
2023 Q3	$70K	Hold	200	–	–	﹤0.01%	594
2023 Q2	$70K	Hold	200	–	–	﹤0.01%	602
2023 Q1	$63K	Hold	200	–	–	﹤0.01%	536
2022 Q4	$58K	Hold	200	–	–	﹤0.01%	560
2022 Q3	$58K	Hold	200	–	–	﹤0.01%	546
2022 Q2	$56K	Hold	200	–	–	﹤0.01%	557
2022 Q1	$52K	Buy	+200	New	+$47.5K	﹤0.01%	579
2021 Q3	–	Sell	-4	Closed	-$1K	–	1077
2021 Q2	$1K	Sell	4 -50	-93%	-$10.5K	﹤0.01%	960
2021 Q1	$12K	Hold	54	–	–	﹤0.01%	712
2020 Q4	$13K	Buy	54 +4	+8%	+$918	﹤0.01%	708
2020 Q3	$14K	Hold	50	–	–	﹤0.01%	657
2020 Q2	$15K	Buy	+50	New	+$13.6K	﹤0.01%	640
2019 Q3	–	Sell	-34	Closed	-$6K	–	923
2019 Q2	$6K	Buy	+34	New	+$5.94K	﹤0.01%	622
2016 Q1	–	Sell	-22	Closed	-$3K	–	738
2015 Q4	$3K	Hold	22	–	–	﹤0.01%	698
2015 Q3	$2K	Hold	22	–	–	﹤0.01%	707
2015 Q2	$3K	Buy	+22	New	+$2.77K	﹤0.01%	696

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bartlett & Co's VRTX Position: Q4 2023 in Review

Bartlett & Co held its Vertex Pharmaceuticals (VRTX) position steady in Q4 2023 at 200 shares worth $82K. The position accounts for ﹤0.01% of the portfolio, ranked #606.

Bartlett & Co first reported a position in VRTX in Q2 2015 and has held it in 17 quarters since. 1,438 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

Bartlett & Co held 200 shares of Vertex Pharmaceuticals worth $82K as of Q4 2023.
Bartlett & Co left its Vertex Pharmaceuticals share count unchanged in Q4 2023.
Vertex Pharmaceuticals made up ﹤0.01% of Bartlett & Co's portfolio in Q4 2023, its #606 holding.
Bartlett & Co first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 17 quarters since.
1,438 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.